A multi-center phase II study of 114 patients aged 60-74 years with AML in first remission has found that reduced-intensity HCT can lead to a low incidence of non-relapse mortality (NRM) and graft-versus-host disease (GVHD). NRM at 2 years was 15%, and grade II-IV acute GVHD occurred in 9.6% of patients, while chronic GVHD occurred in 28% of patients. Two-year disease-free survival was 42%. The authors noted that reduced-intensity conditioning is relatively well tolerated in this patient cohort, and “appears to provide superior outcomes when compared with historical patients treated without HCT.”
Devine SM, et al. J Clin Oncol